Financial Performance - Total revenues for Q1 2025 were $11,201 million, a decrease of 6% compared to $11,865 million in Q1 2024[133] - GAAP diluted earnings per share (EPS) for Q1 2025 was $1.20, a significant increase from a loss of $5.89 in Q1 2024[133] - Non-GAAP diluted EPS for Q1 2025 was $1.80, compared to a loss of $4.40 in Q1 2024[133] - U.S. revenues decreased by 7% to $7,873 million in Q1 2025, impacted by generic competition and redesign of the Medicare Part D program[145][147] - International revenues decreased by 3% to $3,110 million in Q1 2025, primarily due to foreign exchange impacts, but increased by 2% excluding these impacts[148] - Gross product sales for Q1 2025 were $19,874 million, a 3% increase from $19,295 million in Q1 2024[149] - Total revenues for the three months ended March 31, 2025, were $11,201 million, a decrease of 6% compared to $11,865 million in 2024[154] - The Growth Portfolio generated $5,563 million in revenue, reflecting a 16% increase from $4,792 million in the previous year[154] - The Legacy Portfolio saw a significant decline, with total revenues of $5,638 million, down 20% from $7,073 million[154] - Non-U.S. revenues for the total portfolio decreased by 2% to $3,328 million[154] Revenue Changes by Product - Eliquis revenue decreased by 4% to $3,565 million, with U.S. sales down 6% and Non-U.S. sales up 2%[154] - Revlimid revenue dropped 44% to $936 million, with U.S. sales also down 44%[154] - Pomalyst/Imnovid revenue decreased by 24% to $658 million, with U.S. sales down 10%[154] - U.S. revenues for Eliquis decreased 44% in Q1 2025, primarily due to generic erosion and lower average net selling prices[174] - U.S. revenues for Revlimid decreased 10% in Q1 2025, mainly due to lower average net selling prices[174] - U.S. revenues for Camzyos increased 63% in Q1 2025, primarily due to higher demand[164] - U.S. revenues for Krazati increased 116% in Q1 2025, driven by higher demand[166] - U.S. revenues for Cobenfy increased 133% in Q1 2025, attributed to expanded manufacturing capacity and new indication launches[167] Cost Management and Expenses - The company expects to achieve annual cost savings of approximately $2.0 billion by the end of 2027 through its productivity initiative[132] - Total expenses decreased by 65% in Q1 2025, from $23.4 billion in 2024 to $8.2 billion[182] - Research and development expenses decreased by 16% in Q1 2025, totaling $2.3 billion[182] - Selling, general and administrative expenses decreased by 33% in Q1 2025, totaling $1.6 billion[182] - Acquired IPRD charges totaled $188 million in Q1 2025, a decrease from $12,949 million in Q1 2024[186] - Amortization of acquired intangible assets decreased by $1.5 billion in Q1 2025, primarily due to the full amortization of Revlimid[187] Regulatory Approvals and Product Launches - Significant regulatory approvals in Q1 2025 included Opdivo + Yervoy for advanced hepatocellular carcinoma and colorectal cancer in the U.S. and EU[131][141] - The launch of Opdivo Qvantig in January 2025 is expected to enhance the company's oncology portfolio[157] - Augtyro received EC approval for treating ROS1-positive advanced NSCLC and advanced solid tumors expressing NTRK gene fusion in February 2025[205] - Breyanzi was approved by the EC for adult patients with relapsed or refractory FL after two or more lines of systemic therapy in March 2025, based on the Phase II TRANSCEND FL study[205] - Camzyos received manufacturing and marketing approval in Japan for treating adults with oHCM in March 2025, based on results from the global Phase III EXPLORER-HCM study[205] - Opdivo Qvantig injection was recommended for approval by the CHMP for subcutaneous use in March 2025, demonstrating noninferiority in co-primary endpoints compared to its intravenous formulation[206] - Opdivo + Yervoy was approved by the FDA as a first-line treatment for unresectable or metastatic HCC in April 2025, based on the Phase III CheckMate-9DW trial results[206] Tax and Net Income - The effective tax rate for Q1 2025 was 17.1%, significantly improved from (3.4)% in Q1 2024, influenced by a $12.1 billion one-time charge in 2024[190] - Non-GAAP net earnings for Q1 2025 were $3,668 million, compared to a loss of $8,910 million in Q1 2024[196] - Other (income)/expense, net increased by $258 million, resulting in a net income of $339 million in Q1 2025 compared to $81 million in Q1 2024[188] Cash Flow and Debt Management - The net debt position improved by $886 million to $(37,584) million as of March 31, 2025, driven by $2.0 billion cash provided by operations[197] - Cash flow from operating activities was $1,954 million in Q1 2025, down $880 million from $2,834 million in Q1 2024[201] - Cash used in investing activities was $(499) million in Q1 2025, a significant decrease from $(19,618) million in Q1 2024 due to lower acquisition-related payments[203] - Dividend payments amounted to $1.3 billion during Q1 2025, reflecting the company's ongoing commitment to returning value to shareholders[200] - The company had no borrowings outstanding under any revolving credit facility as of March 31, 2025, indicating strong liquidity management[199] Clinical Trial Results - Sotyktu showed positive data in the Phase III POETYK PsA-2 trial, achieving ACR20 response in 54.2% of treated patients compared to 39.4% in placebo after 16 weeks[206] - The Phase III ODYSSEY-HCM trial for Camzyos did not meet its dual primary endpoints in April 2025, leading to updates in the U.S. Prescribing Information[205] - The Phase III RELATIVITY-098 trial for Opdualag did not meet its primary endpoint of recurrence-free survival in February 2025[206] Accounting Policies - The company reported no material changes to critical accounting policies during the three months ended March 31, 2025[207]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Revenues came to $11.2bn, down 6% year-on-year on a constant currency basis. Non-GAAP earnings per share ("EPS") came to $1.80, and GAAP EPS $1.20, compared to $(4.40) and ...

Bristol Myers Squibb (BMY) reported $11.2 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 5.6%. EPS of $1.80 for the same period compares to -$4.40 a year ago.The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $10.73 billion. With the consensus EPS estimate being $1.51, the EPS surprise was +19.21%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

Q1 2025 Results April 24, 2025 Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information This presentation contains statements about Bristol-Myers Squibb Company's (the "Company") future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are ...

Financial Performance - Bristol Myers Squibb reported quarterly earnings of $1.80 per share, exceeding the Zacks Consensus Estimate of $1.51 per share, compared to a loss of $4.40 per share a year ago, representing an earnings surprise of 19.21% [1] - The company posted revenues of $11.2 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.38%, although this is a decrease from year-ago revenues of $11.87 billion [2] - Over the last four quarters, Bristol Myers has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance and Outlook - Bristol Myers shares have declined approximately 14.2% since the beginning of the year, while the S&P 500 has decreased by 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.69 on revenues of $11.35 billion, and for the current fiscal year, it is $6.76 on revenues of $45.82 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution (PRINCETON, N.J., April 24, 2025) – Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squ ...

百时美施贵宝预计全年调整后每股收益6.70美元至7美元，此前预计6.55美元至6.85美元。 ...

FILE PHOTO: The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023.Bristol Myers Squibb on Thursday beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs.The company now expects 2025 revenue to come in between $45.8 billion and $46.8 billion, up from a previous outlook of around $45.5 billion. Bristol Myers also expects full-year adjusted earnings of $6.70 to $7 per share, which c ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

The first-quarter 2025 earnings season for the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector was kicked off last week when bellwether Johnson & Johnson reported strong first-quarter results, beating the estimates for its earnings and sales. JNJ also slightly raised its sales guidance range for the year. Most of the remaining large-cap pharmaceutical companies will report their fi ...